(b)(4).Initial emdr submission.A follow up emdr will be submitted if additional information becomes available.(b)(4).No additional information was provided by kaiser permanente (b)(6).Primevigilance did reach out to obtain with no success.Should additional information be available in the future, the complaint will be re-opened and investigated.All complaints are reviewed during monthly quality/safety meetings.In addition, complaints are trended at monthly quality data analyst meetings and quarterly plant management review meetings.
|
Material no.: unknown batch no.: unknown.It was reported that the patients are experiencing skin rashes.See (b)(4) for reported issue on (b)(6) 2020.Per email: this is the product failure form for the chloraprep skin rashes we have been experiencing more of.I do not have specific lot#s or anything, as it seems it is system wide as well as in the hospitals.Can you reach out to bd and see if they have made changes to the solution, as well as reach out to the kp enterprise and see if there are similar claims? i believe we are well over 20+ cases being reported just at kpco.
|